U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06972628) titled 'Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617' on April 07.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan.
Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap.
The study will enroll up to 30 men with metastatic castration-resistant prostate cancer, with an initial dosing approach that differs...